Josh Enomoto

Josh Enomoto

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Why the Perplexing Science of Vaccines Keeps Novavax Around

Though Novavax is behind in the clinical trial race, that doesn’t necessarily mean NVAX stock is done for. However, investors who want to take a bet must do so very carefully.

The Compelling Science and the Harsh Risks Behind Inovio Pharmaceuticals

Although vaccine plays are inherently risky, the recent robust rally in INO stock is backed by strong and compelling science.

Beyond Meat Stock Has Competition and It’s Tasty

There’s no question that Beyond Meat stock is capitalizing on the enormous popularity of plant-based meat. However, rising competition means that commoditization is a very real threat.

Why Novartis’ Absence From the Covid-19 Vaccine Race Is a Benefit

Although it’s one of the major pharmaceuticals, Novartis didn’t directly jump into the vaccine race. That might have been the best move for Novartis stock.

Don’t Be Afraid To Be Skeptical About Kensington Capital Stock

Thanks to the enormous interest around EVs and associated businesses, Kensington Capital stock has skyrocketed off the potential of solid-state batteries. But this narrative has always been a tricky one for even the best manufacturers.